SurVaxM Vaccine Study for Kids' Brain Tumors

This study is for kids with certain types of brain tumors, like medulloblastoma and glioma. They will receive a vaccine called SurVaxM. This vaccine helps the immune system find and destroy cancer cells by recognizing a protein called survivin. Survivin is common in cancer cells but not in healthy cells. The vaccine will be mixed with Montanide ISA 51, which boosts the immune response, making the vaccine work better. The study has two parts: Priming and Maintenance. In the Priming Phase, participants get four shots over six weeks. In the Maintenance Phase, if the first phase goes well, they will receive shots every eight weeks for up to two years. After treatment, doctors will check for side effects for three years, with visits every three months.

• Length of Study: Up to two years for treatment, plus three years of follow-up.
• Visit Frequency: Every two weeks at first, then every eight weeks.
• Potential Risks: Side effects are monitored, but serious issues are rare.